1,721,316 research outputs found
Highlights of the Annual Congress of the European Association of Nuclear Medicine, Amsterdam 2003
No full textAmong the highlights of this congress, the increasing importance of FDG and PET stands out. In particular, the number of PET/CT scanners is rising within nuclear medicine, as is their scientific and clinical impact. Excellent contributions were also presented on new instrumentation and radiopharmacy, with particular focus on technetium-labelled radiopharmaceuticals, which remain the cornerstone of our specialty. New radiopharmaceuticals are aimed at improving specific targeting, and serve to demonstrate the enormous potential and clinical importance of molecular nuclear medicine. The leitmotif of this congress was "quality", and with this in mind the following concluding remarks on improving quality in nuclear medicine seem apposite: We need to further increase the number of PET, and particularly PET/CT, scanners in Europe, but we must also encourage the development of new radiopharmaceuticals labelled with positron emitters for use with PET scanners. Furthermore, we need to continue to stimulate and support basic research, which is the "life-blood" of our specialty, and to continually propose new ideas and methodologies for improving health care. We also require more help from industry to sustain the production of new radiopharmaceuticals. Most importantly, we must improve interdisciplinary dialogue, clearly defining the role and competence of nuclear medicine in patient care, which spans from prevention to diagnosis, and from therapy decision-making through therapy itself to follow-up. We should reflect more on the excellent science presented at congresses like this one and, on the other hand, on the still limited clinical role of nuclear medicine. It is therefore a priority for each of us, and for our scientific societies in particular, to intensify the dialogue with physicians of other disciplines. Scientific societies now have evidence-based results to which they can refer in urging authorities to simplify the regulation governing research into and commercialisation of new agents and to improve reimbursement of nuclear medicine examinations
A NEW SINGLE-USE DEVICE FOR EX-VIVO LABELLING OF WHITHE BLOOD CELLS WITH RADIOACTIVE ISOTOPES UNDER STERILE CONDITIONS
No full text
Radiolabelled interleukin 2 for in vivo imaging of activated T-lymphocytes
Full text linkThe progress of our understanding and knowledge of the pathophysiology of chronic inflammatory diseases has prompted the development of several new specific receptor-binding peptide radiopharmaceuticals. Data obtained so far on the clinical use of radiolabelled peptides have demonstrated that this approach is safe and effective in vivo for the study of selected cell populations in several inflammatory conditions.
It is now possible to assess the activity of the disease, but also to verify its ultimate effects: cell killing.
New “tailored peptides” are being continuously tested in vivo to match new diagnostic challenges and for therapy decision making and follow-up. It is hoped that by using new molecular approaches, including the development of new tools for high resolution imaging, we will increasingly contribute to the clinical management of patients with inflammatory diseases. In particular radiolabelled-IL2 is a unique example of how these techniques can be revolutionary in the management of patients. Activeted T-cells are constantly present, although in a low percentage, in circulating blood, primary and secondary lymphoid tissues, including oral and gut mucosa. But what is the treshold for pathology? When does a localized increase of activated Tcells requires to be treated, what is the best treatment and how should we follow-up the efficacy of such a treatment? Now that we have the possibility to image in-vivo and non-invasively the tissue distribution of activated T-cells, all these questions require an answer.
Our understanding of human pathology and molecular biology has evolved the clinic of human diseases from the symptomatological classification of the 19th century to a physiopathological classification of disease of the 20th century. The 21st century is giving rise to a biomolecular classification of diseases, also aided both by new tools for high-resolution imaging and by the development of radiolabelled peptides to diagnose and manage inflammatory conditions.
About inflammation and infection
Full text linkABSTRACT: This letter points out the correct definition of inflammation and infection that is important for differential diagnosis. The most common nuclear medicine techniques and interpretation criteria to differentiate inflammation between infection are also briefly mentioned
Scientific production and impact of nuclear medicine in Europe: How do we publish?
No full textWe performed a bibliometric search covering a 1-year period to evaluate the number and the scientific "weight" of nuclear medicine papers published from European as compared with other countries. The scientific impact of our discipline was evaluated according to the impact factor of each publication, and we also aimed to identify those countries and topics that are making the principal contributions to the development of our discipline. To this end, a search on MEDLINE (PubMed) was run to find all peer-reviewed articles published between April 2002 and May 2003, using isotope definitions as search terms. A total of 3,292 publications were identified. Of these, 650 were of no nuclear medicine interest, 229 were reviews and 82 had no country specified. In absolute numbers, Europe leads research in nuclear medicine (939 papers, 38.9%) followed by the USA (608 papers, 25.2%). Among European countries, Germany is the nation that is currently making the greatest contribution to the scientific production of nuclear medicine in Europe. Articles concerning the use of nuclear medicine in oncology account for more than one-quarter of all published nuclear medicine papers
Ormone stimolante la tiroide (TSH) radiomarcato e suo uso per la diagnosi e la terapia dei tumori differenziati della tiroide.
No full text
- …
